Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYAT1 | Q16773 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728993 | 1.00 | KYAT1 (0.57) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL29052500 | 1.00 | KYAT1 (0.57) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL15183794 | 0.90 | MAPT (0.50) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL29052483 | 0.86 | MAPT (0.52) | KYAT1NPSR1MAPTGAAKMT2A | |
| SCHEMBL15047065 | 0.85 | KYAT1 (0.60) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL5442778 | 0.82 | KYAT1 (0.63) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL5442782 | 0.82 | KYAT1 (0.63) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL7925134 | 0.82 | KYAT1 (0.63) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL21504092 | 0.80 | KYAT1 (0.63) | KYAT1NPSR1MAPTGAAMAPK1 | |
| SCHEMBL28276370 | 0.80 | KYAT1 (0.63) | KYAT1NPSR1MAPTGAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163448-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | QURIENT CO., LTD. (KR) | 2021-06-03 | — | — | US | disclosed |
| US-10934274-B2 | Quinoline derivatives as TAM RTK inhibitors | QURIENT CO., LTD. (KR) | 2021-03-02 | — | — | US | disclosed |
| EP-3286177-B1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | QURIENT CO LTD (KR) | 2020-05-06 | — | — | EP | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163448-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF AXL/MER RTK AND CSF1R | CSF1R, CSF3R, FLT3 | KYAT1 3271/4885NPSR1 308/4885MAPT 341/4885 |
| US-10934274-B2 | Quinoline derivatives as TAM RTK inhibitors | TYRO3, MERTK, AXL | KYAT1 3174/4885NPSR1 1382/4885MAPT 2676/4885 |
| US-20180093968-A1 | QUINOLINE DERIVATIVES AS TAM RTK INHIBITORS | TYRO3, MERTK, AXL | KYAT1 3174/4885NPSR1 1382/4885MAPT 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.